Site & patient solutions case studies

A large pharmaceutical company was conducting a Phase 2 study for adults with a BMI of 18-32. They contracted 60 US sites, including 9 Accellacare sites to recruit for two cohorts and conduct the study.

A medical device developer faced clinical evaluation timeline delays due to under-enrolment. Discover how the collaborative partnership between the sponsor and ICON’s Medical Device & Diagnostics Research team steered the study from patient enrolment to FDA submission and approval.

A pharmaceutical sponsor launched a global trial for elderly UTI patients, opening 125 sites across 15 countries. Enrolment lagged at 1 patient per site per month, with 70% non-enrolling. ICON was brought in to rescue the study.

A biotechnology company required vitamin D distribution as an auxiliary medication for a phase 3 MASH and fibrosis clinical study. When the original supplement vendor was unable to support the study’s full global scope, the company engaged ICON’s Accelerated Pharmaceutical Solutions (APS) team to step in on short notice.

The sponsor in this case was a large pharmaceutical company that contracted ICON to manage and streamline the training and compliance workload for their phase 2 Alzheimer’s study.

A biopharmaceutical company was running a global 4-study program evaluating the long-term safety and effectiveness of a study drug in adult patients with a rare, inherited disease impacting the kidneys and other vital organs.

A large pharma sponsor was conducting a Phase 2/3 randomised, placebo-controlled COVID-19 vaccine study. Facing labour and supply shortages, as well as unprecedented safety challenges due to the ongoing pandemic, the sponsor contracted Accellacare to support their staffing, enrollment, and logistics across seven US sites.

A biotechnology company was attempting to recruit 40 paediatric patients in a US phase II oncology study.

Large pharmaceutical company was running a phase II study to assess the efficacy of a study drug in paediatric patients with a rare degenerative genetic disorder. The study required weekly infusions for more than 50 patients in the UK.

A mid sized Pharma organisation was conducting a Phase Ib trial with plans to enroll 188 Non Small Cell Lung Carcinoma patients in Cohort B.

We developed and facilitated a series of Patient Partner Workshops™. Patients engaged in a variety of unique activities designed to stimulate open, honest dialogue among the group.

A mid-sized biopharmaceutical sponsor was conducting a phase 3 study on CDKL5 deficiency disorder, a rare
genetic seizure disorder in children.